Daphnetin
CAS No. 486-35-1
Daphnetin ( 7,8-Dihydroxycoumarin | NSC 633563 )
产品货号. M14627 CAS No. 486-35-1
Daphnetin 是一种天然香豆素衍生物,是一种蛋白激酶抑制剂,抑制 EGFR、PKA 和 PKC,IC50 分别为 7.67 μM、9.33 μM 和 25.01 μM,还具有抗炎和抗氧化活性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥187 | 有现货 |
|
| 10MG | ¥312 | 有现货 |
|
| 25MG | ¥626 | 有现货 |
|
| 50MG | ¥1097 | 有现货 |
|
| 100MG | ¥1611 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥310 | 有现货 |
|
生物学信息
-
产品名称Daphnetin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Daphnetin 是一种天然香豆素衍生物,是一种蛋白激酶抑制剂,抑制 EGFR、PKA 和 PKC,IC50 分别为 7.67 μM、9.33 μM 和 25.01 μM,还具有抗炎和抗氧化活性。
-
产品描述Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.(In Vitro):Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24-48 hours) inhibits the proliferation of ovarian cancer cells.Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24 hours; A2780 cells) induces apoptosis and increases ROS production in a dose-dependent manner.Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24 hours; A2780 cells) induces autophagy through modulation of the AMPK/Akt/mTOR pathway.Daphnetin (7,8-dihydroxycoumarin) (1-10 μM; plasmodium falciparum) exhibits schizontocidal activity in a dose-dependent manner. (In Vivo):Daphnetin (7,8-dihydroxycoumarin) (30 mg/kg; i.p.; daily; for 12 days; BALB/c nude mice) has antitumour activities in a xenograft animal model.Daphnetin (7,8-dihydroxycoumarin) (2.5-10 mg/kg; i.p.; daily; for three days; C57BL/6 mice) inhibits cisplatin-induced inflammation, decreases TNF-α, IL-1β, ROS and MDA production in a dose-dependent manner in kidney tissues. Daphnetin inhibits cisplatin-induced NF-κB activation and up-regulated Nrf2 and HO-1.Daphnetin (7,8-dihydroxycoumarin) (10-100 mg/kg; i.g. and i.p.; every four days, for 30 days; male Kunming outbred strain mice) displays certain schizontocidal activity in vivo.
-
体外实验Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24-48 hours) inhibits the proliferation of ovarian cancer cells.Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24 hours; A2780 cells) induces apoptosis and increases ROS production in a dose-dependent manner.Daphnetin (7,8-dihydroxycoumarin) (0-40 μg/mL; 24 hours; A2780 cells) induces autophagy through modulation of the AMPK/Akt/mTOR pathway.Daphnetin (7,8-dihydroxycoumarin) (1-10 μM; plasmodium falciparum) exhibits schizontocidal activity in a dose-dependent manner. Cell Viability Assay Cell Line:IOSE8C, A2780, SKOV3 and OVCAR8 cells Concentration:0, 5, 10, 20 and 40 μg/mL Incubation Time:24 h and 48 hours Result:Inhibited growth in ovarian cancer cells but not in normal cells.Apoptosis AnalysisCell Line:A2780 and SKOV3 cells Concentration:0, 10, 20 and 40 μg/mL Incubation Time: 24 hours Result:Increased apoptosis in a dose-dependent manner in A2780 and SKOV3 cells.Western Blot Analysis Cell Line:A2780 and SKOV3 cells Concentration:0, 10, 20 and 40 μg/mL Incubation Time:24 hours Result:Increased proapoptotic protein (Caspase 3, Bax, and PARP) expression but decreased antiapoptotic protein (Bcl2) expression.Western Blot Analysis Cell Line:A2780 cells Concentration:0, 10, 20 and 40 μg/mL Incubation Time:24 hours Result:Increased LC3 II and p62 expression in a dose-dependent manner and reduced the expression levels of p-Akt, p-mTOR, but increased the expression level of p-AMPK.
-
体内实验Daphnetin (7,8-dihydroxycoumarin) (30 mg/kg; i.p.; daily; for 12 days; BALB/c nude mice) has antitumour activities in a xenograft animal model.Daphnetin (7,8-dihydroxycoumarin) (2.5-10 mg/kg; i.p.; daily; for three days; C57BL/6 mice) inhibits cisplatin-induced inflammation, decreases TNF-α, IL-1β, ROS and MDA production in a dose-dependent manner in kidney tissues. Daphnetin inhibits cisplatin-induced NF-κB activation and up-regulated Nrf2 and HO-1.Daphnetin (7,8-dihydroxycoumarin) (10-100 mg/kg; i.g. and i.p.; every four days, for 30 days; male Kunming outbred strain mice) displays certain schizontocidal activity in vivo. Animal Model:BALB/c nude mice Dosage:30 mg/kg Administration:Intraperitoneal injection; Daily; for 12 days Result:Decreased tumor volume and weight in a xenograft animal model.Animal Model:Male Kunming outbred strain mice Dosage:10, 50 or 100 mg/kg Administration:Oral gavage and intraperitoneal injection; every four days, for 30 days Result:Reduced the number of parasites in mice.
-
同义词7,8-Dihydroxycoumarin | NSC 633563
-
通路Angiogenesis
-
靶点EGFR
-
受体EGFR| PKA| PKC
-
研究领域Inflammation/Immunology
-
适应症——
化学信息
-
CAS Number486-35-1
-
分子量178.14
-
分子式C9H6O4
-
纯度>98% (HPLC)
-
溶解度DMSO: 35 mg/mL (196.47 mM)
-
SMILESO=C1C=CC2=CC=C(O)C(O)=C2O1
-
化学全称7,8-dihydroxy-2H-1-benzopyran-2-one
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Yang EB, et al. Biochem Biophys Res Commun, 1999, 260(3), 682-685.
产品手册
关联产品
-
AZD-9291
一种有效的、选择性的、第三代不可逆突变型 EGFR 抑制剂,对 L858R-T790M/L858R/L861Q 的 IC50 分别为 1/12/5 nM。
-
NRC-2694
NRC-2694 是表皮生长因子受体 (EGFR) 的拮抗剂。它具有抗癌和抗增殖特性。
-
Petosemtamab
Petosemtamab (MCLA 158) 是一种抗EGFR (Kd: 0.22 nM) 和抗 LGR5 (Kd: 0.86 nM) 单克隆抗体 (mAb)。Petosemtamab 导致 LGR5+ 癌细胞中的 EGFR 信号传导阻断和受体降解。Petosemtamab 可用于头颈部鳞状细胞癌 (HNSCC)、转移性结直肠癌 (CRC) 等实体瘤的研究。
021-51111890
购物车()
sales@molnova.cn

